In patients with PSA of “grey zone” (4.0-10.0 ng/ml, n=339), IPP was indicated to be associated with positive rate of prostate cancer and integrating it with tPSA could significantly increase the predictive accuracy7. This evidence concerns the gene IPP and prostate carcinoma.